Post hoc analysis of 3 RCTs in women with moderate-to-severe menopausal vasomotor symptoms: fezolinetant vs placebo improved work productivity loss by 12.4% (10.2% where HT unsuitable) over 52 weeks, with estimated savings of 3,878 GBP per woman a year in the UK.
Secondary analysis
Morga et al. Estimated impact of fezolinetant versus placebo on work productivity and indirect costs among women experiencing vasomotor symptoms associated with menopause